|
Xiaoyun Lu studied Medicinal Chemistry at China Pharmaceutical University and received her Ph.D. in 2010. After working for six years in Guangzhou Institutes of Biomedicine and Health (GIBH), she moved to the School of Pharmacy at Jinan University in 2016. Her research interests include the design of new generation of kinase inhibitors to overcome clinical resistance of cancers. She has been involved in the design and development of EGFR, DDRs, FGFR4, and TRKs inhibitors. Among them, two drug-like inhibitors of kinase have been into clinic. She has published about 100 SCI papers and co-invented 40 patents, received the Special Professor of Changjiang Scholars of Ministry of Education (2024), the National Outstanding Youth Fund (2019), China Pharmaceutical Association - Servier Pharmaceutical Chemistry Award (2014) and Chinese Academy of Sciences Lu Jiaxi Young Talent Award (2015). She currently serves as editorial Board Member of Journal of Medicinal Chemistry, Acta Pharmaceutica Sinica B, Chinese Chemical Letters, etc. |
